© 2022 MJH Life Sciences and Cancer Network. All rights reserved.
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
September 20, 2022
Closing out their panel on GVHD management, expert hematologist/oncologists share their hope for future evolution in the treatment landscape.
September 13, 2022
Comprehensive discussion on the pharmacologic treatment armamentarium available for patients with chronic graft vs host disease.
Expert hematologist/oncologists highlight challenges in staging chronic graft vs host disease and share strategies to optimize cGHVD assessment.
September 06, 2022
After reviewing a clinical scenario of chronic graft vs host disease, panelists consider the importance of different allogeneic transplant types.
Shared insight on treatment approaches toward patients with acute graft vs host disease who experience partial response to frontline therapy.
August 30, 2022
Focusing on pharmacologic options, expert panelists review frontline treatment strategies for patients with acute graft vs host disease.
Expert hematologist/oncologists share their perspectives on use of biomarkers to help prognosticate graft vs host disease.
August 23, 2022
Centering discussion on a scenario of acute graft vs host disease, expert panelists consider optimal workup of a patient showing signs of GVHD.
Shared insight on the pathophysiology of graft vs host disease, with specific regard for differences between acute GVHD vs chronic GVHD.
August 16, 2022
Hematologist/oncologists provide a broad overview of the pharmacologic agents used to prevent graft vs host disease at their institutions.